eCOA
J.P.M. Week 2025
The J.P. Morgan Healthcare Conference returned to San Francisco this year, bringing significant deals and strategic shifts that signal where healthcare is headed. While this year’s weather outside was dry and sunny, a substantial change from the prior two years' rainy conferences, the conditions inside differed, with several companies making waves.
Challenge fuels change: Medable impact report
Medable’s 2024 was a year of exceeding key milestones and helping our customers reach new heights.
Take a look at the difference Medable has made with our year-end impact report.
The big impact of Medable AI
In November, we released an update to Medable Studio titled Medable AI. This latest update furthers Studio's unique value proposition, offering sponsors and CROs unprecedented control over the study creation and launch process, as well as scalability, speed, and streamlining of operations. This provides the easiest, fastest path to study launch in the industry to date.
If this already sounds like something you could use, check out a demo or an in-depth look at its feature set here.
For everyone else, read below to discover what exactly Medable AI has to offer.
Medable beats forecasted FPI date by taking eCOA off the critical path
A top-10 global pharmaceutical company came to Medable looking to standardize and scale their weight management trials. The trial was driven by a master protocol with multiple sub-studies across 70+ research sites.
The partner was concerned about the participant and site experience, particularly participant enrollment and study startup timelines, as the trial required participants to enroll through the master protocol before enrolling into a sub-study.
Read ahead to see how Medable accomplished this, beat the forecasted FPI date, and more.
How platforms solved clinical trials’ disparate data problem across eCOA, eConsent, and more
Our world is drowning in data.
Humanity generates a staggering 402.74 million terabytes of information every day. From the countless videos we stream to the endless social media scrolling, our global digital footprint is growing exponentially. This data deluge is reshaping industries, influencing our lives, and posing unprecedented challenges.
Within clinical trials, rapidly evolving technologies are enabling researchers to capture new data points as trials grow more complex. However, this poses new challenges in managing clinical trial data.
Maximize Control and Transparency on the Path to Study Go-Live
In this webinar learn how to simplify the historically complicated, black-box processes around eCOA solution deployment, content storage and visualization, and global go-live with Medable Studio
Explore Medable Studio
A decade ago, our founders’ experiences in clinical research and life sciences drove them to create Medable, a simple cloud-based platform that could improve theconduct of trials. Over the last ten years, we’ve conducted nearly 400 trials on our platform, continually refining it to provide a better experience for sites, patients, and caregivers.Today, we’re excited to announce that our customers are entering a new era of control, ease of use, and simplicity.
Use Case: Integrating consent data to reduce administrative burden
A top-10 pharmaceutical company was looking to reduce the amount of administrative burden on their clinical trial sites and themselves. The sponsor sought to find a vendor that could use one eConsent system to manage paper and electronic consent. Additionally, they sought to use the central eConsent system to populate the clinical trial sites’ IRB and EDC systems, as well as some internal systems.
Control and transparency: Solving sponsors’ key challenges in eCOA development and study launch with Studio
There’s no doubt that study launches come with extremely high stakes for sponsors requiring precise coordination over numerous critical activities across multiple stakeholders, including regulatory bodies, ethics committees, investigator sites, and internal teams. Now, sponsors can see exactly what’s happening live across assessments, instruments, translations, and more. This is true whether their internal teams handle launch activities or whether vendors handle them, a stark contrast to the traditional technology development process.
Creating success with digital measures
The landscape of clinical trials is undergoing a significant transformation as digital measures and digital health technologies (DHTs) continue to evolve and prove their worth.
As of December 2023, approximately 1,550 clinical trials worldwide utilized wearable devices, representing about 2% of all trials. While this percentage may seem small, it marks a steady increase since 2014, and the momentum is set to accelerate.
Medable platform delivers >90% eCOA adherence and scalability
A top-10 American pharmaceutical company came to Medable looking to conduct an extensive weight management master protocol clinical trial with multiple sub-studies across 70+ research sites. The client was concerned about the participant experience, as the trial required participants to enroll through the master protocol before enrolling into a sub-study. Additionally, they wanted to reuse and scale the solution for future trials without compromising the site and patient experience.
Learn how Medable was able to accomplish this and more.
Evidence generation evolved
The pharmaceutical industry faces a daunting challenge: it takes an average of 12 years and $3 billion to bring a new drug to patients, with the FDA approving an average of 50 new therapies yearly.
This pace is inadequate to address humanity's needs and our own future goal of helping the industry produce ten times the number of treatments it does today.
A significant bottleneck is the lengthy clinical trial process, where Phase 3 studies alone can span three years or more. However, a critical factor compounding these timelines is the difficulty in recruiting sufficient patients for these crucial studies, often adding up to 2 years to the already protracted journey.
Use case: How a top-10 pharma digitized and standardized participant pain body maps
A top-10 pharmaceutical company was looking to standardize the conduct of their diabetic polyneuropathy trials for future use.
Specifically, the client was looking to digitize their paper “body map” forms. These are used by participants to indicate the severity of pain on their bodies.
Traditionally administered on paper, body map assessments had been a source of potential inefficiencies and errors.
The client’s goal was to co-create and own their body maps, while simplifying and streamlining the process for future trials.